Generally, Alzheimer's disease affects eldery population, and there are some patients who have difficulty swallowing a tablet or granule formulation with water due to the decline in their ability to swallow or the water enters into their trachea while taking the medication... Eisai's Press Release -
Friday, March 21, 2008
Eisai, Application for Aricept Oral Jelly Formulation in Japan
Generally, Alzheimer's disease affects eldery population, and there are some patients who have difficulty swallowing a tablet or granule formulation with water due to the decline in their ability to swallow or the water enters into their trachea while taking the medication... Eisai's Press Release -
Neurobiological Technologies and Buck Institute, to Develop Novel Treatment for Alzheimer's Disease
AD is a neurodegenerative disease that, in its most common form, occurs in people over 65 years old and is the most common cause of dementia afflicting 24 million people worldwide.AD Research at the Buck Institute focuses on signal transduction pathways that may explain all of the different, yet seemingly opposed theories of AD, namely that AD is caused by either an overabundance of amyloid-B (AB) peptide, or neurofibrillary tangles that build up inside the nerve cells. Current studies at the Buck are focused on a naturally occurring protein that has been shown in both cell culture and mice to inhibit the production of amyloid-B (AB) peptides while simultaneously facilitating the growth and preservation of nerve fibers in the brain... Neurobiological Technologies' Press Release -
Monday, March 17, 2008
Bar Harbor BioTechnology : New Line of StellARrays
March 6, 2008 - Bar Harbor BioTechnology Inc. announced the launch of its new line of human StellARray™ products for gene expression research today. This initial offering of 43 different biological pathways for scientists to select from includes many major human diseases. Configured to perform gene expression or gene copy number experiments these new Real-Time PCR arrays are the first of their kind in the field of gene expression research."Scientists researching human diseases like obesity, osteoporosis, and Alzheimer's disease have a new method for detecting subtle changes in how a group of genes are expressed. That could lead to a breakthrough in their research," says Robert Phelps, President of Bar Harbor BioTechnology Inc... Bar Harbor BioTechnology's Press Release -
Friday, March 14, 2008
Power3 Medical , Three Hundred Patient Clinical Validation Study of Its Nuropro(R) Diagnostic Test for Alzheimer's and Parkinson's Disease
Mar 13 2008 - Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, commenced a three hundred patient clinical validation study of its NuroPro diagnostic test for Alzheimer’s disease and Parkinson’s disease... Power3 Medical's Press Release -
Monday, March 10, 2008
Pharmatrophix Alzheimer's Drug Discovery Foundation to Develop Drugs to Prevent Neurodegenerative Disease
PharmatrophiX is developing a series of small molecule compounds called "neurotrophin mimetics" that mimic the function of neurotrophins. Neurotrophins are naturally occurring proteins that are responsible for the development, health and survival of neurons. These mimetics are the most promising compounds to date that target the degeneration caused by the toxic protein beta-amyloid which kill neurons, impair memory and may be the cause of Alzheimer's disease... ADDF's Press Release -
Wednesday, March 5, 2008
Hunter-Fleming and Newron, continuation of phase II study for HF0220 in patients with Alzheimer’s disease
03/03/2008 - Newron Pharmaceuticals S.p.A. (“Newron”, SWX: NWRN), a research and development company focused on novel CNS and pain therapies, and Hunter-Fleming Ltd., a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders, today announced that Hunter-Fleming has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue a Phase II safety and tolerability study with HF0220 in patients with Alzheimer’s disease (AD). The recommendation is based on the results of an interim review of the study being undertaken by Hunter-Fleming.
On February 9, 2008, Newron signed an agreement to acquire 100% of the issued share capital of Hunter-Fleming. The Phase IIa multi-centre, double blind placebo controlled, biomarker trial includes 40 patients in study centres in the UK and Sweden, who are treated for 28 days at different doses of HF0220... [PDF] Newron's Press Release -
Debiopharm's Debio 9902 SR in Alzheimer’s disease, Clinical Update
March 4, 2008 - Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced that following a meeting of the independent Data Safety Monitoring Board (DSMB), the Company received a recommendation to continue its Phase II BRAINz study with Debio 9902 SR (sustained release) for the treatment of Alzheimer’s disease (AD), without modification.The DSMB’s objective is to monitor the well being and safety of patients participating in a study and to review the safety data throughout its duration... Debiopharm's Press Release -
Power3 Medical, Patent Application for Forty-Seven Protein Biomarkers
Mar 5 2008 -Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, filed a U.S. Utility Patent application for forty-seven protein biomarkers of neurodegenerative disease in human blood serum.Power3 Medical has determined the blood serum concentrations of these forty-seven biomarkers in samples from more than 750 neurodegenerative disease patients and normal control subjects. The results have shown that this group of biomarkers is useful in the differential diagnosis of Alzheimer’s disease (AD) from normal control individuals, patients with non-Alzheimer’s dementias, and patients with Parkinson’s disease or ALS (Lou Gehrig’s disease). Eighteen million people worldwide have AD; because the early signs of Alzheimer’s disease are often hard to distinguish from normal signs of aging, many patients are not diagnosed until the neuronal damage caused by this disease is extensive... Power3 Medical Products' Press Release -